Our main focus is the production of children's vaccines which are included in the National Immunisation Program of the Russian Federation.

Other key areas of the “Nanolek” product portfolio include in-house medicines designed for the treatment of oncological, autoimmune and orphan diseases.

Vaccines

Pnemotex®

The pneumococcal polysaccharide conjugated adsorbed thirteen-valent vaccine is indicated for the prevention of pneumococcal infection caused by Streptococcus pneumoniae serotypes 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F and 23F in adults and children 2 months of age and older. The results of clinical trials make it possible to recommend the PNEMOTEX® vaccine for the active immunization for the prevention of pneumococcal infection in children according to the 2 + 1 scheme as part of the National Vaccination Schedule and in adults as part of the vaccination schedule according to epidemic indications of the Russian Federation. Registration number LP-007205. The holder of the registration certificate and the manufacturer LLC «Nanolek».

PENTAXIM®

A combined vaccine for the prevention of the five most dangerous childhood infections: whooping cough, diphtheria, tetanus, polio, as well as diseases caused by Hemophilus influenzae (Haemophilus influenza type b). The registration certificate belongs to Sanofi S.A. In accordance with the National Preventive Vaccinations Calendar of the Russian Federation, the vaccination course consists of three injections of the drug with an interval between vaccinations of 45 days, respectively, at the age of 3, 4 and a half, and 6 months, with revaccination at the age of 18 months.

MENACTRA®

A polysaccharide conjugated vaccine for the prevention of meningococcal infections in 4 serogroups (A, C, Y, W), for children (from 9 months), adolescents and adults. It has been registered and used in Russia since 2014, and has been produced in Russia since 2022. According to the Headway Company report (2015–2021), Menactra® is supplied to 85 regions of the country for immunization of children and adults. Since 2014 more than 1.5 million doses have been used in the regions. The vaccine has been used globally for more than 15 years and has been registered in more than 70 countries around the world.

PoliovacSin®

A cultured, purified, concentrated, inactivated, liquid vaccine from attenuated Sabine strains. It protects against three types of polio virus — an incurable disease that can lead to complete paralysis. It was created within the framework of the Invak project, organized by Nanolek together with the Chumakov Center for Immunobiological Preparations of the Russian Academy of Sciences. According to the plans, the vaccine will appear on the market in 2023.

Oncology

Bavencio

Avelumab is a human immunoglobulin Gl, a maintenance therapy drug for bladder cancer. It binds to PD-L1 and blocks its interaction with PD-1 and B7.1 receptors, eliminating the suppressive effect of PD-L1 against cytotoxic CD8+ T-lymphocytes. As a result, the antitumor T-cell response is restored. Developed by Merck.

Brukinza

A low-molecular-weight Bruton tyrosine kinase inhibitor (TKB) zanubrutinib, developed by BeiGene scientists. It is used as monotherapy or in combination with other drugs for the treatment of malignant tumors from B-lymphocytes. Provides complete and sustained inhibition of TCB protein by increasing biological digestibility, half-life and selectivity. In 2021, it was approved by the Ministry of Health of the Russian Federation for the treatment of adult patients with mantle cell lymphoma (MCL).

Darzalex

The antitumor drug daratumumab is the first fully human monoclonal antibody that acts on the CD38 surface protein, which is largely expressed on all myeloma cells, regardless of the stage of the disease. The drug uses CD38-mediated immune mechanisms (complement-dependent cytotoxicity, antibody-dependent cell-mediated cytotoxicity and antibody-dependent phagocytosis) that destroy tumor cells.

Lomustine

Lomustin was developed by Nanolek together with JSC Biocom. An antitumor drug of alkylating action from the nitrosourea group also inhibits key enzymatic processes, changing the structures and functions of proteins and enzymes. It is used for both mono- and combination therapies of oncological diseases, such as primary and metastatic brain tumors, lung, stomach, intestinal cancer, lymphogranulomatosis (Hodgkin's disease), malignant metastatic melanoma, and multiple myeloma.

Neupomax

Filgrastim is a recombinant human granulocyte colony stimulating factor (G-CSF). It stimulates the formation of neutrophils which are then released into the peripheral blood from the bone marrow. It is used to treat neutropenia of various origins. The drug was obtained using recombinant DNA technology from cells of the bacterium Escherichia coli, whose genetic apparatus contains a gene encoding the protein G-CSF.

Stibevara

Antitumor agent. Recombinant hyperchymeric (humanized, close to human) monoclonal antibodies IgG1 selectively bind and inhibit the biological activity of vascular endothelial growth factor (VEGF). The drug was created using recombinant DNA technology.

Tretinoin

Tretinoin is a retinoid, a carboxylic acid form of vitamin A, is also known as all-trans-retinoic acid, or ATRA. It is a first-generation retinoid commonly used to treat acne and follicular keratosis.

Orphan

Hunterase

Hunterase® (idursulfase beta) is a drug for the long—term treatment of patients with Hunter syndrome (type II mucopolysaccharidosis). It is a purified form of the lysosomal enzyme iduronate-2-sulfatase — recombinant human iduronate-2-sulfatase (RFIDs). The efficacy and safety of Hunterase was confirmed during two clinical studies in male patients with Hunter syndrome aged 38 months to 35 years for 24-52 weeks (see the instructions for medical use of the drug).

Special care

Lemtrada

Alemtuzumab is a humanized IgGl kappa monoclonal antibody that binds to CD52 glycoproteins and reduces the number of circulating B and T lymphocytes. It is used for the treatment of active relapse-remitting multiple sclerosis in adults who have had two or more exacerbations in the last two years. The owner of the registration certificate is Genzyme Europe.